Intellia Therapeutics (NASDAQ:NTLA) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald restated their overweight rating on shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) in a research note published on Monday morning, Benzinga reports. The firm currently has a $65.00 price objective on the stock. Several other research firms have also commented on NTLA. BMO Capital Markets raised their price target on shares of […]
More Stories
BP (NYSE:BP) Upgraded at StockNews.com
StockNews.com upgraded shares of BP (NYSE:BP – Free Report) from a hold rating to a buy rating in a report...
BMO Capital Markets Raises Antero Resources (NYSE:AR) Price Target to $34.00
Antero Resources (NYSE:AR – Free Report) had its price target increased by BMO Capital Markets from $33.00 to $34.00 in...
Boeing (NYSE:BA) Price Target Cut to $195.00
Boeing (NYSE:BA – Free Report) had its target price cut by Deutsche Bank Aktiengesellschaft from $225.00 to $195.00 in a...
AMN Healthcare Services (NYSE:AMN) Earns “Market Outperform” Rating from JMP Securities
JMP Securities restated their market outperform rating on shares of AMN Healthcare Services (NYSE:AMN – Free Report) in a report...
Albany International (NYSE:AIN) PT Lowered to $81.00 at TD Cowen
Albany International (NYSE:AIN – Free Report) had its target price reduced by TD Cowen from $95.00 to $81.00 in a...
Truist Financial Boosts AECOM (NYSE:ACM) Price Target to $119.00
AECOM (NYSE:ACM – Free Report) had its price target lifted by Truist Financial from $108.00 to $119.00 in a research...